Too Old to Operate22h
Impact of Dupilumab on Skin Protein and Metabolite Composition in AD
The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...
pharmaphorum10d
NICE changes stance on Sanofi's Dupixent for severe asthma
The final appraisal document for Dupixent (dupilumab) has given the green ... It is the second indication for the IL-4 and IL-13 inhibitor cleared for use by the NHS in England and Wales after ...
Hosted on MSN3mon
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
Sanofi SNY and Regeneron’s REGN Dupixent (dupilumab), an injectable monoclonal antibody that blocks IL-4/IL-13 signaling, is an approved therapy for multiple allergic and atopic diseases.
Interleukin inhibitors remain a strong growth driver in dermatology
Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.